PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33519451-0	2020	Pioglitazone-Mediated Attenuation of Experimental Colitis Relies on Cleaving of Annexin A1 Released by Macrophages.	Pioglitazone	0-12	annexin A1	Mus musculus	80-90	
33519451-8	2020	Metalloproteinase-9 (MMP-9) and inactive 33 kDa AnxA1 levels were increased in the colon of diseased WT mice, which were reduced by pioglitazone treatment.	Pioglitazone	132-144	annexin A1	Mus musculus	48-53	
33519451-9	2020	Cytokine secretion, reactive oxygen species generation and MMP-9 expression caused by lipopolysaccharide (LPS) treatment in AnxA1-expressing RAW 264.7 macrophages were reduced by pioglitazone treatment, effects not detected in AnxA1 knockdown macrophages.	Pioglitazone	179-191	annexin A1	Mus musculus	124-129	
33519451-9	2020	Cytokine secretion, reactive oxygen species generation and MMP-9 expression caused by lipopolysaccharide (LPS) treatment in AnxA1-expressing RAW 264.7 macrophages were reduced by pioglitazone treatment, effects not detected in AnxA1 knockdown macrophages.	Pioglitazone	179-191	annexin A1	Mus musculus	227-232	
33519451-10	2020	LPS-mediated increase of AnxA1 cleaving in RAW 264.7 macrophages was also attenuated by pioglitazone treatment.	Pioglitazone	88-100	annexin A1	Mus musculus	25-30	
33519451-11	2020	Finally, pioglitazone treatment increased extracellular signal-regulated kinase (ERK) phosphorylation in AnxA1-expressing RAW 264.7 macrophages, but not in AnxA1-knockdown macrophages.	Pioglitazone	9-21	annexin A1	Mus musculus	105-110	
33519451-12	2020	Thus, our data highlight AnxA1 as a crucial factor for the therapeutic actions of pioglitazone on IBDs.	Pioglitazone	82-94	annexin A1	Mus musculus	25-30